ライフサイエンスコーパス: disopyramide

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 73 obstructive HCM patients not treated with disopyramide.

2 We studied the open-channel blockers disopyramide and flecainide, and the lidocaine derivativ

3 All-cause annual cardiac death rate between disopyramide and non-disopyramide-treated patients did n

4 4%) could not be satisfactorily managed with disopyramide and required major invasive interventions b

5 The antiarrhythmic agent disopyramide and various serotonin reuptake blockers hav

6 xertional dyspnea (beta-blockers, verapamil, disopyramide) and the septal myotomy-myectomy operation,

7 ence was strong for amiodarone, propafenone, disopyramide, and sotalol.

8 in 118 obstructive HCM patients treated with disopyramide at 4 HCM treatment centers.

9 irds of obstructed HCM patients treated with disopyramide could be managed medically with amelioratio

10 In wild-type channels, 100 microM disopyramide decreased mean open time from 1.64 +/- 0.08

11 pulses at 150-ms interpulse intervals during disopyramide exposure.

12 Patients were followed with disopyramide for 3.1 +/- 2.6 years; dose 432 +/- 181 mg/

13 ssessed the long-term efficacy and safety of disopyramide for patients with obstructive hypertrophic

14 However, long-term efficacy and safety of disopyramide has not been shown in a large cohort.

15 mortality through stepped management, adding disopyramide in appropriately selected patients, and whe

16 suggest the detection of new metabolites of disopyramide in the population samples.

17 It has been reported that disopyramide may reduce left ventricular outflow gradien

18 rophysiological testing on quinidine (n=54), disopyramide (n=2), or both (n=4).

19 zed specific mutation, open-channel block by disopyramide persists.

20 gents for rhythm maintenance are amiodarone, disopyramide, propafenone, and sotalol (drugs listed in

21 Disopyramide therapy does not appear to be proarrhythmic

22 diac death rate between disopyramide and non-disopyramide-treated patients did not differ significant

23 Mortality in the disopyramide-treated patients was compared with 373 obst

24 Disopyramide was added in 221 (74%) patients and pharmac

25 ty-eight patients (66%) were maintained with disopyramide without the necessity for major non-pharmac

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。